A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
NCT00165789
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
E2007
Sponsor
Eisai Inc.